Company intelligence / Profile preview

Biofusion Therapeutics

Bengaluru, Karnataka, Indiain.linkedin.com ↗

Ownership: Private
Development stage: Other

Overview

The company developed BCA101, a bifunctional monoclonal antibody fusion that targets both EGFR and neutralizes TGFβ in the tumor microenvironment to induce immune activation and suppress tumor growth. No clinical trial results are publicly available; activity appears limited to preclinical/translational studies as per available literature.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodyFusion protein
Industry: Biotech

Partnerships

Parent-subsidiary relationship with Biocon

Beyond the preview

Go deeper on Biofusion Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biofusion Therapeutics.

Explore the full profile